Barbara White Selected Research

lenabasum (ajulemic acid)

10/2022	Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical Trial.
8/2022	Lenabasum Reduces Porphyromonas gingivalis-Driven Inflammation.
1/2022	Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo effects of LenabasumTM.
7/2021	A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationale.
1/2021	Safety and efficacy of lenabasum in a phase 2 randomized, placebo-controlled trial in adults with cystic fibrosis.
1/2020	Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic Sclerosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Barbara White Research Topics

Disease

8	Lung Diseases (Lung Disease) 11/2007 - 04/2002
5	Dermatomyositis (Dermatopolymyositis) 10/2022 - 11/2011
5	Inflammation (Inflammations) 10/2022 - 10/2018
5	Diffuse Scleroderma (Progressive Systemic Sclerosis) 07/2021 - 11/2002
5	Fibrosis (Cirrhosis) 01/2020 - 04/2002
5	Systemic Lupus Erythematosus (Libman-Sacks Disease) 11/2011 - 06/2009
5	Rheumatoid Arthritis 11/2011 - 01/2006
4	Pneumonia (Pneumonitis) 01/2021 - 04/2002
4	Systemic Scleroderma (Systemic Sclerosis) 01/2020 - 12/2002
4	Psoriasis (Pustulosis Palmaris et Plantaris) 07/2010 - 07/2008
3	Dyspnea (Shortness of Breath) 11/2007 - 06/2006
3	Interstitial Lung Diseases (Interstitial Lung Disease) 11/2007 - 11/2003
3	Pulmonary Fibrosis (Fibrosing Alveolitis) 12/2003 - 05/2003
2	Neoplasms (Cancer) 12/2012 - 07/2004
2	Asthma (Bronchial Asthma) 02/2011 - 04/2009
2	Pulmonary Hypertension 11/2003 - 11/2003
1	Skin Diseases (Skin Disease) 10/2022
1	Endocarditis 01/2021
1	Pericarditis 01/2021
1	Pericardial Effusion 01/2021
1	COVID-19 01/2021
1	Cystic Fibrosis (Mucoviscidosis) 01/2021
1	Amyloidosis 01/2013
1	Disease Progression 01/2013
1	Familial Amyloidosis (Hereditary Amyloidosis) 01/2013
1	Thyroid Neoplasms (Thyroid Cancer) 12/2012
1	Myositis (Idiopathic Inflammatory Myopathies) 11/2011
1	Rheumatic Diseases (Rheumatism) 11/2011
1	Polymyositis 11/2011
1	Chills 07/2010
1	Lymphopenia (Lymphocytopenia) 07/2010
1	Headache (Headaches) 07/2010
1	Myocardial Infarction 03/2010
1	Graft vs Host Disease (Graft-Versus-Host Disease) 07/2009
1	Coinfection 07/2009
1	Respiratory Hypersensitivity 04/2009
1	Familial Primary Pulmonary Hypertension 12/2006
1	Idiopathic Pulmonary Fibrosis 12/2006
1	Body Weight (Weight, Body) 06/2006
1	Juvenile Arthritis (Juvenile Idiopathic Arthritis) 06/2006
1	Infections 06/2006
1	Glioblastoma (Glioblastoma Multiforme) 07/2004
1	Pathologic Processes 11/2003

Drug/Important Bio-Agent (IBA)

10	Monoclonal AntibodiesIBA 01/2016 - 04/2009
6	lenabasum (ajulemic acid)IBA 10/2022 - 01/2020
5	Interferon Type IIBA 11/2011 - 07/2008
5	CytokinesIBA 07/2010 - 05/2002
5	Cyclophosphamide (Cytoxan)FDA LinkGeneric 11/2007 - 04/2002
3	CannabinoidsIBA 03/2022 - 01/2021
3	sifalimumabIBA 11/2011 - 01/2010
3	siplizumabIBA 07/2010 - 07/2009
3	Interferon-alpha (Interferon Alfa)IBA 03/2010 - 06/2009
3	Etanercept (Enbrel)FDA Link 06/2006 - 01/2006
3	ChemokinesIBA 12/2003 - 05/2002
2	Hydroxychloroquine (Plaquenil)FDA LinkGeneric 10/2022 - 01/2021
2	Biomarkers (Surrogate Marker)IBA 01/2021 - 11/2009
2	Messenger RNA (mRNA)IBA 01/2021 - 12/2003
2	enokizumabIBA 02/2011 - 04/2009
2	ametantrone (HAQ)IBA 05/2007 - 09/2002
2	AntibodiesIBA 01/2006 - 04/2002
2	Penicillamine (Cuprimine)FDA Link 02/2004 - 11/2002
2	Proteins (Proteins, Gene)FDA Link 12/2003 - 12/2002
1	Cannabinoid Receptors (Cannabinoid Receptor)IBA 10/2022
1	CB2 Cannabinoid ReceptorIBA 01/2021
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2021
1	Dronabinol (THC)FDA LinkGeneric 10/2018
1	AcidsIBA 10/2018
1	Prednisolone (Predate)FDA LinkGeneric 10/2018
1	anabasumIBA 10/2018
1	inebilizumabIBA 01/2016
1	Prealbumin (Transthyretin)IBA 01/2013
1	Thyroglobulin FDA Link 12/2012
1	InterferonsIBA 11/2011
1	Granulocyte-Macrophage Colony-Stimulating Factor Receptors (GM-CSF Receptor)IBA 09/2011
1	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 09/2011
1	mavrilimumabIBA 09/2011
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 07/2010
1	Pharmaceutical PreparationsIBA 03/2010
1	Biological ProductsIBA 07/2009
1	Interleukin-9 (Interleukin 9)IBA 04/2009
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 07/2008
1	Collagen Type I (Type I Collagen)IBA 06/2008
1	Infliximab (Remicade)FDA Link 01/2006
1	Chemokine CCL18IBA 12/2003
1	CollagenIBA 12/2003
1	Aligeron (AS 2)IBA 11/2003
1	Transforming Growth Factor beta (TGF-beta)IBA 08/2003
1	Oncostatin MIBA 08/2003
1	Interleukin-4 (Interleukin 4)IBA 08/2003

Therapy/Procedure

9	Therapeutics 01/2021 - 05/2003
3	Lung Transplantation 12/2006 - 04/2002
1	Prostheses and Implants (Prosthesis) 01/2021
1	Ambulatory Care (Outpatient Care) 01/2021
1	Lasers (Laser) 01/2021
1	Transcatheter Aortic Valve Replacement 01/2021
1	Liver Transplantation 01/2013
1	Thyroidectomy 12/2012
1	Radiotherapy 12/2012
1	Biological Therapy 07/2009
1	Organ Transplantation 07/2004